Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics, Inc. (VERV)
:VERV
VERV Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Verve Therapeutics News
VERV FAQ
What was Verve Therapeutics, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Verve Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Verve Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Verve Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Verve Therapeutics, Inc. overvalued?
According to Wall Street analysts Verve Therapeutics, Inc.’s price is currently Undervalued.
Does Verve Therapeutics, Inc. pay dividends?
Verve Therapeutics, Inc. does not currently pay dividends.
What is Verve Therapeutics, Inc.’s EPS estimate?
Verve Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Verve Therapeutics, Inc. have?
Currently, no data Available
What happened to Verve Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Verve Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VERV
Company Description
Verve Therapeutics, Inc.
Verve Therapeutics (VERV) is a biotechnology company focused on developing transformative genetic medicines for cardiovascular disease. The company leverages cutting-edge gene editing technologies to create single-course gene-editing medicines that have the potential to permanently reduce the risk of coronary artery disease. Verve's innovative approach aims to address the underlying genetic causes of cardiovascular disease, which is one of the leading causes of mortality worldwide.
Verve Therapeutics (VERV) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Cartesian Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Olema Pharmaceuticals
―
Sana Biotechnology
―
Ownership Overview
―
Insiders
11.12%
Mutual Funds
― Other Institutional Investors
88.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---